These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11363022)

  • 1. New type of HIV drug.
    Treat Rev; 1995 Nov; (no 20):4. PubMed ID: 11363022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E
    Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
    [No Abstract]   [Full Text] [Related]  

  • 3. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
    De Clercq E
    AIDS; 1994 Jul; 8(7):1020-1. PubMed ID: 7524543
    [No Abstract]   [Full Text] [Related]  

  • 4. Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
    AIDS Treat News; 1995 Oct; (no 232):4. PubMed ID: 11362877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of resistance mutants of viral polymerases.
    Oxford JS; al-Jabri AA; Stein CA; Levantis P
    Methods Enzymol; 1996; 275():555-600. PubMed ID: 9026659
    [No Abstract]   [Full Text] [Related]  

  • 6. Site-directed mutagenesis of HIV reverse transcriptase to probe enzyme processivity and drug binding.
    Beard WA; Wilson SH
    Curr Opin Biotechnol; 1994 Aug; 5(4):414-21. PubMed ID: 7520785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
    Kleim JP; Winters M; Dunkler A; Suarez JR; Riess G; Winkler I; Balzarini J; Oette D; Merigan TC
    J Infect Dis; 1999 Mar; 179(3):709-13. PubMed ID: 9952383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.
    Rübsamen-Waigmann H; Huguenel E; Paessens A; Kleim JP; Wainberg MA; Shah A
    Lancet; 1997 May; 349(9064):1517. PubMed ID: 9167463
    [No Abstract]   [Full Text] [Related]  

  • 9. Nucleoside drug resistance in HIV-1 reverse transcriptase.
    Yadav PN; Yadav JS; Modak MJ
    Nat Struct Biol; 1995 Mar; 2(3):193-5. PubMed ID: 7539709
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials.
    Artico M
    Farmaco; 1996 May; 51(5):305-31. PubMed ID: 8767842
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
    Kilby JM; Saag MS
    Adv Exp Med Biol; 1996; 394():291-8. PubMed ID: 8815693
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
    J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.
    Rübsamen-Waigmann H; Huguenel E; Shah A; Paessens A; Ruoff HJ; von Briesen H; Immelmann A; Dietrich U; Wainberg MA
    Antiviral Res; 1999 May; 42(1):15-24. PubMed ID: 10333139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW
    Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming resistance to reverse transcriptase inhibitors.
    Pieribone V
    GMHC Treat Issues; 1995 Sep; 9(9):8-9. PubMed ID: 11362911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
    de Clercq E; Snoeck R
    Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.